About LEO Pharma
LEO Pharma is a company based in Copenhagen (Denmark) founded in 1908. LEO Pharma has raised $560.38 million across 3 funding rounds from investors including Nordic Capital. LEO Pharma has completed 3 acquisitions, including Peplin, Replay and Timber Pharmaceuticals. LEO Pharma offers products and services including Dermatology Treatments. LEO Pharma operates in a competitive market with competitors including Incyte, Formation Bio, Arcutis, DermBiont and Evommune, among others.
- Headquarter Copenhagen, Denmark
- Stage Unicorn
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Leo Pharma A/S
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$560.38 M (USD)
in 3 rounds
-
Latest Funding Round
$1.54 M (USD), Private Equity Round
Mar 31, 2022
- Investors
-
Employee Count
Not available
-
Investments & Acquisitions
Peplin
& 2 more
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of LEO Pharma
LEO Pharma offers a comprehensive portfolio of products and services, including Dermatology Treatments.
Products for managing skin conditions through research-based solutions
People of LEO Pharma
Unlock access to complete
Unlock access to complete
Software Development Team
55 people
Senior Team
39 people
Human Resources and Administration
37 people
Leadership Team
36 people
Finance and Accounting
36 people
Sales and Marketing
34 people
Product Management Team
15 people
Head Team
14 people
Unlock access to complete
Funding Insights of LEO Pharma
LEO Pharma has successfully raised a total of $560.38M across 3 strategic funding rounds. The most recent funding activity was a Private Equity Round of $1.54 million completed in March 2022. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in LEO Pharma
LEO Pharma has secured backing from 1 investor, including venture fund investors. Prominent investors backing the company include Nordic Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
-
|
Locked | Locked | Locked |
Investor details for LEO Pharma
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by LEO Pharma
LEO Pharma has strategically engaged in corporate development activities, having acquired 3 companies. Notable acquisitions include Peplin, Replay and Timber Pharmaceuticals.
Investment portfolio details for LEO Pharma
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Genomic reprogramming platforms for DNA writing and delivery are offered.
|
Locked | Locked | 2021 | Locked | |
|
Therapeutics for dermatological rare diseases are developed.
|
Locked | Locked | 2011 | Locked | |
|
Topical gel for the treatment of actinic (solar) keratosis.
|
Locked | Locked | 1999 | Locked |
Complete acquisition details for LEO Pharma
Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.
- Transaction dates
- Acquired stakes
- Disclosed values
- Domains and locations
Verified entity values are shown only after access is granted.
Financial Statements - LEO Pharma
Detailed financials for LEO Pharma
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Leo Pharma Comparisons
Peer comparison for LEO Pharma
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of LEO Pharma
LEO Pharma operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Incyte, Formation Bio, Arcutis, DermBiont and Evommune, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Small molecules are developed for cancer and skin disease treatments.
|
|
| Locked | Locked | Locked |
AI-powered drug discovery platform for various diseases
|
|
| Locked | Locked | Locked |
Immunotherapeutic solutions for dermatological conditions are developed.
|
|
| Locked | Locked | Locked |
Microbial therapeutics for skin diseases are developed.
|
|
| Locked | Locked | Locked |
Developer of therapeutic options for chronic inflammatory disorders
|
Detailed competitors of LEO Pharma
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Leo Pharma
Complete news archive for LEO Pharma
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about LEO Pharma
LEO Pharma was founded in 1908 and raised its 1st funding round 101 years after it was founded.
LEO Pharma is headquartered in Copenhagen, Denmark.
Christophe Bourdon is the current CEO of LEO Pharma.
LEO Pharma is a funded company, having raised a total of $560.38M across 3 funding rounds to date.
Developer of drugs for treating dermatology diseases. It offers variety of medicines such as topical creams and ointments, oral tablets, and injectable biologics for the treatment of psoriasis, eczema, and rare diseases. The pipeline products include Tralokinumab for atopic dermatitis and Delgocitinib a topical pan-JAK inhibitor for chronic hand eczema.
LEO Pharma's top competitors include Formation Bio, Arcutis and Incyte.
LEO Pharma offers Dermatology Treatments.
LEO Pharma has made 3 acquisitions, including Peplin, Replay, and Timber Pharmaceuticals.
LEO Pharma has 1 investor. Key investors include Nordic Capital.
The valuation of LEO Pharma is $2.28B as of Mar 2022.